|
8. Other Gastric
Diseases
Partial (antral)
or total gastric volvulus is a rare cause of acute upper abdominal pain
and vomiting. These obstructions can arise by themselves, or as torsion
within a hiatus hernia. Volvulus within a hernia is not uncommon in the
elderly, when there may be no symptoms. The belief that twisting
obstruction poses an important risk to the blood supply is probably
unjustified. Gastric aspiration is followed by surgical relief of the
volvulus in those who present with obstruction.
Sudden
gross gastric distention and acute dilatation of the stomach can arise
after any form of upper abdominal surgery, including cholecystectomy, and
especially after vagotomy, after childbirth and in diabetic coma. The
causes are uncertain. Vomiting of relatively clear gastric contents is
succeeded by the production of dirty brown or feculent material and the
development of abdominal distention. Prompt decompression with a
large-bore stomach tube and intravenous fluid replacement are required.
After a variable interval the condition should then resolve spontaneously.
8.1.1 GASTRIC RUPTURE
Acute,
nontraumatic, spontaneous rupture of the stomach is a rare, catastrophic
and poorly understood event. The majority of ruptures occur on the lesser
curvature. They have also been reported to occur during upper
gastrointestinal radiography using barium, sodium bicarbonate ingestion,
nasal oxygen therapy, cardiopulmonary resuscitation and labor, and during
the postpartum period.
Hypertrophic
pyloric stenosis is an idiopathic condition that may occur in infants or
adults. The muscle of the pyloric canal is unduly hypertrophied. Infantile
hypertrophic pyloric stenosis is more common in boys than in girls (the
sex ratio is approximately 10:1), is a frequent anomaly (its incidence is
about 3 per 1,000 live births) and is thought to be due to a combination
of genetic predisposition and some abnormality of fetal or early postnatal
development. Symptoms usually develop in the first few weeks after birth
and characteristically consist of copious projectile vomiting of the
gastric contents after feeding. On examination there is usually visible
gastric peristalsis; a lump can be felt abdominally in the region of the
pylorus. Barium-meal examination is not usually necessary but will confirm
the presence of a narrow segment, 1-2 cm long, at the pylorus. The
condition must be distinguished clinically from esophageal atresia (which
involves onset at birth of difficulties with swallowing) and duodenal
obstruction/atresia (which involves bile-stained vomitus). A minor
proportion of all cases settle in the first two to three months with
conservative management with anticholinergic drugs, but most patients will
require early surgery with Ramstedt's procedure (pyloromyotomy).
Occasionally,
adult patients present with obstructive symptoms resulting from pyloric
stenosis associated with muscular hypertrophy. This is rarely if ever
caused by recurrence of infantile pyloric stenosis; it is usually
associated with juxtapyloric peptic ulceration, but sometimes the problem
seems to be due to primary hypertrophic stenosis arising in adult life.
The differential also includes pyloric mucosal diaphragm and annular
pancreas. Pyloric obstruction requires pyloroplasty together with a
procedure such as vagotomy if there is an associated ulcer.
8.2.1 GASTRIC DIVERTICULA
Gastric
diverticula occur most commonly near the cardia on the lesser curve, but
occasionally are found in the prepyloric region. They seldom cause
symptoms. Their principal importance lies in the likelihood of confusion
with gastric ulceration.
8.2.2 PSEUDOLYMPHOMA
Localized
lymphoid hyperplasia of the stomach is also known as pseudolymphoma. The
lesions are raised, flat or nodular folds, and are often associated with
gastric ulceration. The etiology of this condition remains unclear, but
Helicobacter pylori infection has been implicated. It is difficult to
exclude lymphoma using radiology or endoscopic biopsy; thus, a resected
specimen is required for diagnosis.
8.2.3 GASTRIC INFECTIONS
AND INFESTATIONS
Gastric
acid provides a bactericidal barrier against infection. Acid-suppressive
pharmacotherapy, hypochlorhydria or gastric surgery may increase the risk
of bacterial infection. Recent attention has been turned to Helicobacter
pylori, a spiral bacillus found in the upper gastrointestinal tract,
particularly the gastric antrum. H. pylori has been associated with
chronic gastritis in addition to peptic ulcer disease.
Helicobacter
pylori infection is now recognized to be a major causative factor
associated with a spectrum of gastroduodenal disease. It is found in about
95% of patient with gastritis and 100% with chronic active gastritis. It
is found in 90-95% of patients with duodenal ulcer and 60-80% of patients
with gastric ulcer. It is also highly associated with gastric carcinoma
and gastric lymphoma. The association of H. pylori infection with nonulcer
dyspepsia is more controversial and as yet not convincingly substantiated.
Viral
infections such as cytomegalovirus (CMV) and herpes simplex virus are very
often found in immunocompromised hosts. They are associated with gastric
erosions, although CMV has been found in intact mucosa. Cultures or
endoscopic biopsies and smears demonstrating intranuclear inclusions are
helpful in establishing a diagnosis. Candida albicans is commonly found in
the gastric ulcers or erosions of immunocompromised hosts. Candidal
infection should be a consideration in an ulcer that fails to heal. In the
immunocompromised host, parasites such as Strongyloides stercoralis may
become overwhelmingly disseminated. Histoplasmosis and mucormycosis
involving the stomach are rare causes of gastric ulceration and bleeding.
8.2.3.1 Helicobacter pylori
gastritis
Helicobacter
pylori (H. pylori) is a small (3 x 0.5 µm) gram-negative, micro-aerophilic
urease-producing rod-shaped bacillus, which has been closely linked to
both acute and chronic active type B gastritis, especially of the antrum ( Figure
8). H. pylori is an important pathogenic factor in peptic
ulcer disease.
H. pylori
is present in almost all cases of chronic active gastritis, which most
commonly involves antral inflammation but may spread to the whole stomach
over time. H. pylori does not colonize areas of intestinal metaplasia, but
has been seen in the distal esophagus of some patients with Barrett's
esophagus.
The source
of H. pylori is unknown, although person-to-person spread is probably
demonstrated by intrafamilial clustering and a high prevalence of
seropositivity in institutionalized persons, those of low economic status,
and populations in less developed countries. The prevalence of H. pylori
infection increases with age; in Western countries it is uncommon before
the third decade but thereafter increases with seropositivity at the rate
of approximately 1% per year of age.
Most people
with H. pylori-associated gastritis are asymptomatic and have
normal-appearing gastric mucosa at endoscopy. The histologic spectrum of
H. pylori-associated gastritis ranges from minimal to severe inflammation,
but the organisms noted in the mucous layer are associated with severe
depletion of mucus and an intense inflammation, which most often is
chronic, although neutrophils can be noted in some instances. Eradication
of H. pylori with antibiotics has resulted in a marked lessening in the
severity of the gastritis.
8.2.3.1.1 Diagnosis
The
organism can be identified on histology with conventional hematoxylin- and
eosin-stained sections at high-power magnification, but is more easily
seen with the Warthin-Starry or the modified Giemsa stains. The
enzyme-linked immunosorbent assay (ELISA) is the most widely employed
serologic method; its sensitivity and specificity are greater than 90%.
Rapid urease tests can be performed on tissue biopsies in the endoscopy
unit since H. pylori produces large amounts of urease, which can convert
urea into ammonia and carbon dioxide. Rapid urease tests involve urease
and pH indicator gel, into which the biopsy is placed. The presence of H.
pylori results in an alkaline pH of the medium and a color change when the
pH rises. Approximately 75% of the positive tests occur between 20 minutes
and 1 hour, and 90% are positive between 6 and 24 hours. Carbon-urea
breath tests using carbon 13C and 14C employ
carbon-labeled urea that is fed to the patient and is subsequently
hydolyzed by the H. pylori urease, resulting in the formation of ammonia
and carbon dioxide. This labeled carbon dioxide in the breath is then
measured.
8.2.3.1.2 H. pylori
association with peptic ulcer disease
Numerous studies have established the close association of antral H.
pylori and peptic ulcer disease. Over 90% of patients with duodenal ulcer
have H. pylori identified in gastric antral biopsies. The association for
gastric ulcer and H. pylori is up to 85%. Although ulcers can be healed
with a variety of agents that do not eradicate H. pylori, in these cases
relapse is common. However, when the H. pylori organism is eradicated the
impact on the subsequent course of duodenal ulcer is dramatic. The
recurrence rate in patients in whom H. pylori is eradicated ranges from
0-4% per year. This is in marked contrast to those who remain H.
pylori-positive, whose recurrence rates vary from 40-80% per year.
H. pylori
infection is associated with doudenal ulcer by way of an antral-predominant
gastritis that is accompanied by a decrease in somatostatin and an
increase in gastrin. This may augment gastric acid secretion, which may
already be high as a result of genetic factors. Increased gastric acid
secrection leads to gastric metaplasia in the duodenum, which can be
colonized by H. pylroi leading to duodenal bulb inflammation, duodenitis
and duodenal ulcer. The ulcer diathesis may reflect more damaging strains
of the organisms, greater density of the infecting organisms or an
exaggerated host inflammatory response (Figure
9).
TABLE
10. Eradication rates for H. pylori
|
| Bismuth
triple therapy |
PPI + 1
antibiotic |
PPI + 2
antibiotics |
| (2 weeks) |
(2 weeks) |
(1 week) |
|
| 90-98% (metronidazole-sensitive) |
70-85% (clarithromycin) |
88-94% (metronidazole/clarithromycin) |
| 31-63% (metronidazole-resistant) |
55-70% (amoxicillin) |
75-96% (amoxicillin/clarithromycin)
79-90% (amoxicillin/metronidazole) |
|
The therapy
for the eradication of H. pylori has evolved over the past decade (Table
10). The early regimen of bismuth triple therapy included a
bismuth compound (PeptoBismol®) plus metronidazole and
tetracycline or bismuth plus metronidazole and amoxicillin. The therapy is
effective in patients with metronidazole-sensitive H. pylori infection but
not very effective in those with metronidazole-resistant strains. This
regimen has limited compliance because of dosing frequency and adverse
effects.
Therapy
later evolved to combinations of a proton pump inhibitor (PPI) and one
antibiotic, usually clarithromycin. Eradication rates with a PPI plus
clarithromycin are usually between 70 and 85%. The addition of a second
antibiotic to the regimen, usually metronidazole, has led to much higher
eradication rates, such as 88-94% for a PPI plus metronidazole and
clarithromycin. With amoxicillin and clarithromycin the eradication rates
are between 75 and 96%; the rates decrease about 10% with amoxicillin and
metronidazole compared to the previous two combinations.
8.2.3.1.3 Nonulcer
dyspepsia and H. pylori
The
role of H. pylori infection in nonulcer dyspepsia remains an important
question. There may be a subset of patients with nonulcer dyspepsia whose
symptoms are due to H. pylori infection. However, many patients harboring
H. pylori are symptom-free. Acute infection with H. pylori is associated
with belching, pyrosis and malaise, and may be associated with decreased
gastric acid secretion. At present, there is no evidence to suggest that
the presence of H. pylori is associated with any particular symptom
cluster related to functional dyspepsia.
|